ClinicalTrials.gg
RecruitingNCT07703878Updated Nov 4, 2026

A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors

A Phase 1 interventional study of GS-1206 in Solid Tumor, sponsored by Gilead Sciences. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 4, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
302
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to learn more about the study drug GS-1206, including its safety, tolerability, and antitumor activity in adult participants with solid tumors.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • All individuals must have a tumor with protocol-specified mutation as determined by local health-authority approved test.
  • For Part A (including backfill cohorts): Individuals with confirmed advanced or solid tumors who have progressed following treatment in the advanced or metastatic setting known to confer clinical benefit, unless the individual refused, is intolerant to, or is not eligible for standard-of-care (SOC) treatment.
  • For Part B dose expansion, individuals with protocol-specified tumor types will be enrolled.

Key Exclusion Criteria:

  • Use of any of the therapies listed below within the specified time frames:

    1. drugs (drugs not marketed for any indication) within 28 days prior to Cycle 1 Day 1.
    2. Anticancer biologic agent or immunotherapy within 28 days prior to Cycle 1 Day 1.
    3. Anticancer chemotherapy or targeted approved small molecule therapy within 21 days prior to Cycle 1 Day 1, or 42 days for nitrosoureas or mitomycin.
    4. Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started within 14 days prior to planned Cycle 1 Day 1 are not permitted. Exceptions: hormonal therapy, bisphosphonates, somatostatin analogues, and leuprolide are permitted if started at least 14 days prior to Cycle 1 Day 1.
    5. Major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal/biliary stent, ) within 28 days prior to Cycle 1 Day 1, and any toxicity or complications have recovered to Grade 1 or less.
    6. Radiation therapy within 21 days prior to Cycle 1 Day 1. Exception: limited (eg, pain palliation) radiation therapy is allowed if any radiation associated toxicity is resolved to Grade 1 or less, and the radiation is not administered to a target lesion.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
302 participants (estimated)

Study arms

  • Experimental
    Part A: Dose Escalation

    Participants will receive escalating doses of GS-1206 monotherapy one time daily up to 35 cycles.

    Drug: GS-1206

  • Experimental
    Part B: Dose Expansion

    Participants will be enrolled in different indication specific cohorts. Participants will receive GS-1206 monotherapy at the recommended dose one time daily up to 35 cycles.

    Drug: GS-1206

Interventions

  • DrugGS-1206

    Administered Orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs)

    Time frame: First dose up to 21 days post first dose

  2. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAE) Based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

    Time frame: First dose date up to 30 days post last dose (Up to 3 years)

  3. Percentage of Participants Experiencing Clinical Laboratory Abnormalities Based National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

    Time frame: First dose date up to 30 days post last dose (Up to 3 years)

Secondary outcomes

  1. Plasma Concentrations of GS-1206 and its Metabolites After Single Dose and Repeated Dose Administration

    Time frame: Predose and postdose up to end of treatment (up to 2 years)

  2. Pharmacokinetic (PK) Parameter: Cmax of GS-1206 and its Metabolites

    Cmax is defined as the maximum observed concentration of drug

    Time frame: Up to 2 years

  3. PK Parameter: Tmax of GS-1206 and its Metabolites

    Tmax is defined as the time (observed time point) of Cmax

    Time frame: Up to 2 years

  4. PK Parameter: AUC0-24h of GS-1206 and its Metabolites

    AUC0-24h is defined as the partial area under the concentration versus time curve from time 0 to time 24

    Time frame: Up to 2 years

  5. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who have measurable disease at baseline and have achieved complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and assessed by the investigator at the local site.

    Time frame: Up to 3 years

  6. Duration of Response (DOR)

    DOR is defined as the measurement from the time of first response (CR or PR) as assessed by the investigator at local site, per RECIST v1.1 until the date of first documented disease progression or death, whichever occurs first.

    Time frame: Up to 3 years

  7. Best Overall Response (BOR)

    BOR is defined as the best response recorded from first dosing date until disease progression identified by RECIST v1.1, death, or the participant discontinues study treatment, whichever occurs first.

    Time frame: Up to 3 years

  8. Progression-Free Survival (PFS)

    PFS is defined as the time from first dosing date until disease progression or death from any cause, whichever comes first as measured per RECIST v1.1.

    Time frame: Up to 3 years

  9. Disease Control Rate (DCR)

    DCR is defined as the measurement by the percentage of participants who achieve confirmed response of CR or PR or stable disease.

    Time frame: Up to 3 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Sep 2029, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 15, 2026
StartActual
Jul 17, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • NEXT Oncology Dallas · Dallas, United States
  • START San Antonio, LLC · San Antonio, United States
Show 2 removed
  • NEXT Oncology Dallas · Texas City, United States
  • START San Antonio, LLC · Texas City, United States
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • NEXT Oncology Dallas · Dallas, United States
    • START San Antonio, LLC · San Antonio, United States
    Show 2 removed
    • NEXT Oncology Dallas · Texas City, United States
    • START San Antonio, LLC · Texas City, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07703878
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Jul 17, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion